Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in newly diagnosed type 1 diabetes mellitus
2010-020166-20Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Canakinumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Stimulated C-peptide AUC at 12 months. Started Dec 2010; status: terminated.
02
Drugs
canakinumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2010-020166-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020166-20.